A well integrated pharma company, Aurobindo Pharma, parent company of Aurohealth, is among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. Our customers include premium multi-national companies. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India. The company operates 16 manufacturing facilities worldwide. Two of which are based in the United States and support the Aurohealth product portfolio.
Aurolife
AurolifePharma LLC is part of Aurobindo group of companies and a fast growing corporation. We are a generic pharmaceuticals company specializing in the development, manufacturing and marketing of generic pharmaceutical products. In addition to several formulations under manufacture, we have a robust pipeline of products. We aim to provide healthcare at economical prices to make this a healthier world to live in.
Aurobindo Pharma India
AuroMedicsPharma LLC is a pharmaceutical company that develops, manufactures, markets and distributes generic injectable products. Our mission is to develop as many injectable products for the US institutional market as possible, providing a consistent and reliable supply, at a fair price and of the highest quality. We are very customer-focused organization that continuously seeks ways to be a reliable source for our customers’ needs.
Our targets include injectable products already off patent where there is a market demand, injectable products utilized in the institutional market that are on, or frequently on, the FDA shortage list, as well as injectable products coming off patent. In addition to ANDA products, we are also developing “value-added” injectable products that will be approved by FDA via the 505 (b)(2) route.
AuroMedicsPharma LLC commenced business in June 2011 and is a wholly owned subsidiary of AurobindoPharma, responsible for generic injectable pharmaceutical products in the USA. AuroMedics leverages the development, API and sterile finished product manufacturing strengths and resources of our parent company augmented by a team of generic injectable industry-seasoned professionals who possess the industry knowledge and experience, and relationships to create a company with a very broad, unique product portfolio in a short period of time.
Auromedics
Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, AurobindoPharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.
AurobindoPharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Through cost effective manufacturing capabilities and a few loyal customers, the company entered the high margin specialty generic formulations segment. In less than a decade AurobindoPharma today has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.
The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets. Leveraging on its large manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, it aims to achieve USD 2 billion revenues by 2015-16. Aurobindo’s nine units for APIs / intermediates and seven units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.
A well integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. Our customers include premium multi-national companies.. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. AurobindoPharma is among the largest filers of DMFs and ANDAs from India.